U.S., Oct. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07212868) titled 'The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery' on Sept. 22.
Brief Summary: The goal of this study is to understand the role of glucagon signal on glucose metabolism in individuals with and without bariatric surgery. The study is involved with measuring glucose metabolism with glucagon infusion and glucagon receptor blockade. We use an investigational drug called REMD 477. "Investigational" means that the has not yet been approved by the U.S. Food & Drug Administration (FDA). REMD-477 is a monoclonal antibody (an antibody made by cloning a unique white blood cell) that blocks the effect of glu...